Shopping Cart
- Remove All
- Your shopping cart is currently empty
CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $32 | In Stock | |
10 mg | $52 | In Stock | |
25 mg | $116 | In Stock | |
50 mg | $198 | In Stock | |
100 mg | $318 | In Stock | |
200 mg | $473 | In Stock | |
1 mL x 10 mM (in DMSO) | $44 | In Stock |
Description | CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM). |
In vitro | CCG-100602 blocks the expression of MRTF-A/SRF-activated genes. CCG-100602 (3-30?μM) decreases the number of adherent hASC cells[1]. |
Molecular Weight | 478.82 |
Formula | C21H17ClF6N2O2 |
Cas No. | 1207113-88-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (208.85 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.